胶质瘤疫苗试验中治疗相关癫痫发作的Meta分析
该Meta分析纳入53项前瞻性临床试验、共2002例疫苗治疗的弥漫性胶质瘤患者,评估疫苗接种后癫痫发作发生率。任意级别治疗相关癫痫发作的合并发生率为19.3%(95%CI: 16.7–22.2%),严重癫痫发作不良事件为4.3%(95%CI: 2.9–6.4%)。在对照试验中,疫苗组与对照组的任意级别癫痫发作风险(RR 1.20,95%CI: 0.89–1.62)及严重癫痫发作风险(RR 1.06,95%CI: 0.65–1.73)相似。
要点
- 胶质瘤疫苗治疗中任意级别癫痫发作合并发生率为19.3%。
- 严重癫痫发作不良事件发生率为4.3%。
- 对照试验显示疫苗未显著增加癫痫发作风险。
核心结论
- 约19%的胶质瘤患者在疫苗治疗及试验监测期间出现癫痫发作。
- 对照试验中等确定性显示疫苗与对照治疗的癫痫风险相似。
- 多数胶质瘤疫苗试验缺乏癫痫相关数据,可能因未归因于疫苗治疗。
研究设计与样本
- 系统检索MEDLINE、Embase和Web of Science数据库,筛选临床试验并审查参考文献。
- 纳入组织学确诊弥漫性胶质瘤患者的前瞻性癌症疫苗试验,排除未报告癫痫发生率或缺乏全部不良事件数据的研究。
- 最终纳入53项研究、2002例疫苗治疗患者;采用随机效应广义线性混合模型计算合并比例,对照试验用Mantel-Haenszel随机效应法进行二分类结局Meta分析。
主要发现
- 任意级别治疗相关癫痫发作发生率为19.3%(95%CI: 16.7–22.2%)。
- 严重癫痫发作不良事件发生率为4.3%(95%CI: 2.9–6.4%)。
- 对照试验中任意级别癫痫发作风险疫苗组与对照组相似(RR 1.20,95%CI: 0.89–1.62,I2=8.5%)。
- 严重癫痫发作风险亦相似(RR 1.06,95%CI: 0.65–1.73,I2=0%)。
- 树突状细胞疫苗、肿瘤细胞疫苗和肽疫苗之间癫痫风险无差异(p=0.67)。
关键数值与推荐
- 严重不良事件定义为常见不良事件评价标准(CTCAE)3级或以上(当数据可用时)。
- 癫痫发生率通过随机效应广义线性混合模型计算合并比例。
- 对照试验二分类结局采用Mantel-Haenszel随机效应法进行Meta分析。
临床怎么用
- 胶质瘤疫苗治疗期间应关注癫痫发作,约五分之一患者可能出现任意级别发作。
- 严重癫痫发作发生率约4%,需在试验监测中予以重视。
- 对照试验数据支持疫苗治疗未显著增加癫痫风险,但证据确定性中等。
- 未来胶质瘤试验应整合标准化详细癫痫追踪以改善反应评估。
局限性
- 多数胶质瘤疫苗试验未报告癫痫相关数据,可能因缺乏对疫苗治疗的归因。
- 分析基于不良事件报告,可能存在报告偏倚或不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Epilepsy is commonly associated with gliomas, with glioma-neuron hyperexcitable interactions promoting tumor growth. Glioma vaccines are a promising form of immunotherapy, however immune-mediated effects on hyperexcitability are poorly understood. Seizures induce a proinflammatory state, whereas gliomas manipulate the microenvironment to evade adaptive immunity. This meta-analysis aimed to evaluate the incidence of seizures after glioma vaccine therapy as a clinical marker of peritumoral hyperexcitability. METHODS: Studies were identified by query of the MEDLINE, Embase, and Web of Science databases with filtering for clinical trials and review of references. Inclusion criteria were prospective trials of cancer vaccines in patients with histologically confirmed diffuse glioma. Studies were excluded if seizure incidence was not reported or if data for all adverse events (AEs) regardless of treatment attribution was unavailable. Serious AEs were defined as grade 3 or higher by the Common Terminology Criteria for Adverse Events when available. Seizure incidence was calculated by pooled proportions with random effects using a generalized linear mixed model. Binary outcome meta-analysis of controlled trials was performed using the Mantel-Haenszel method with random effects. RESULTS: After applying pre-screening exclusion criteria, there were 125 studies screened for seizure-related AEs, and 53 studies with 2002 vaccine-treated patients were included in the final analysis. Treatment-emergent seizures of any grade occurred in 19.3% of patients (95% CI: 16.7–22.2%). Serious seizure AEs occurred in 4.3% (95% CI: 2.9–6.4%). In controlled trials, seizure rates of any grade were similar between vaccine and control groups (RR 1.20, 95% CI: 0.89–1.62, I2 = 8.5%), as well as for serious seizure AEs (RR 1.06, 95% CI: 0.65–1.73, I2 = 0%). There were no differences observed in seizure risk between dendritic cell, tumor cell, and peptide vaccines (p = 0.67). CONCLUSION: Seizure-related data were not available for most glioma vaccine trials, likely due to lack of attribution to vaccine treatment. Using AE reporting, approximately 19% of patients had seizures during vaccine therapy and trial monitoring. In controlled trials, there was moderate certainty of similar seizure risk associated with vaccine versus control treatment. Integrating standardized detailed seizure tracking into future glioma trials may improve response assessments.
引用
- Mc Carthy L, Andersen BM, Wen PY, et al. Meta-analysis of treatment-emergent seizures in glioma vaccine trials. J Neurooncol. 2026. PMID: 41689733. doi:10.1007/s11060-026-05460-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。